<DOC>
	<DOCNO>NCT02897817</DOCNO>
	<brief_summary>The aim study evaluate , 6 month , rate patient whose adherence injectable MTX remain strong improve accord patient-reported outcome .</brief_summary>
	<brief_title>Treatment Adherence Injectable Methotrexate Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient ( ≥ 18 year old ) Patients diagnosis RA confirm ACR/EULAR ( 2010 ) Classification Criteria Rheumatoid Arthritis Patients : currently treat oral MTX require switch injectable MTX* currently treat injectable MTX* eligible change MTX injection device* Patients inform accept computer process medical data right accesss correction . Patients refuse participate study unable fill patient diary . *On basis product market time submission study Oversight Authorities ( Méthotrexate Biodim® , Metoject® imeth® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Treatment adherence</keyword>
</DOC>